Polo-Like Kinase 1

11/01/2023 - "Polo-like kinase 1 (PLK1) is a promising drug target; PLK1 inhibitors (PLK1i) have been investigated in solid cancers and are more effective in TP53-mutated cases. "
10/09/2018 - "Polo-like kinase 1 (PLK-1) inhibitors have shown promising results in tumor cells. "
03/01/2019 - "In the present study, anti-PLK1 (Polo-like kinase 1) potential of the eight FDA-approved (2017) anti-cancer drugs have been explored using molecular docking approach. "
01/01/2018 - "Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors."
11/01/2013 - "Current clinical trials with polo-like kinase 1 inhibitors in solid tumors."

08/01/1995 - "The nucleotide sequence of the entire coding regions shows that this clone, designated Plk1(polo like kinase 1), is identical with STPK13 previously cloned from murine erythro-leukemia cells. "
08/01/2012 - "At present, the number of clinical trials that are registered with the European Organization for Research and Treatment of Cancer (EORTC) and with the US National Cancer Institute, which investigate the efficacy of Polo-like kinase 1 (Plk1) inhibitors against solid tumors and different types of leukemia is growing. "
01/01/2023 - "Polo-like kinase 1 (PLK1) modulates leukemia cell apoptosis, proliferation, and cell cycle arrest in the progression of acute lymphoblastic leukemia (ALL). "
01/07/2015 - "We found that the PLK1 protein was highly expressed in leukemia cell lines as well as 73.3% (11/15) of pediatric acute myeloid leukemia (AML) samples. "
02/20/2003 - "Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)."

11/26/2022 - "The latter was based on application of the PandaOmics target-ID algorithm coupled with in vitro studies that revealed polo-like kinase 1 (PLK1) as a potential therapeutic candidate in sarcoma patients with high CEP135 levels and poor survival. "
01/01/2015 - "Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression."
01/01/2015 - "In order to develop novel targeted therapies, we tested the efficacy of polo-like kinase 1 (PLK-1) inhibitor (TAK-960) in sarcoma. "
08/01/2010 - "Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. "

01/01/2022 - "Polo-like kinase 1 is related with malignant characteristics and inhibits macrophages infiltration in glioma."
01/01/2021 - "Materials and methods: Real-time quantitative PCR (qRT-PCR) was applied to measure the expression of circ-ZNF609, miRNA-1224-3p (miR-1224-3p) and Polo-like kinase 1 (PLK1) in glioma tissues and cell lines. "
11/01/2018 - "In conclusion, our results suggest that down-regulation of PLK1 protein enhanced the inhibition of TMZ on glioma stem cells, suggesting its clinical value to adverse TMZ resistance in glioma treatment."
01/01/2018 - "The expression of PLK1 protein in glioma tissues was also determined by immunohistochemistry staining. "
09/01/2012 - "Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma."

01/01/2018 - "The aim of this study is to investigate whether Polo-like kinase 1 (PLK1) ameliorates sepsis-induced intestinal barrier dysfunction in the intestinal epithelium. "
12/01/2023 - "Polo-like kinase 1 promotes sepsis-induced myocardial dysfunction."
12/29/2022 - "Here, we report a protective role of polo-like kinase 1 (PLK1) in intestinal barrier integrity during sepsis. "
01/01/2020 - "Polo-like kinase 1 protects intestinal epithelial cells from apoptosis during sepsis via the nuclear factor-κB pathway."
01/01/2023 - "Polo-like kinase 1 (PLK1) is widely studied in cancer, while its role in sepsis is poorly understood. "